BioSpace News Archive

Bio-Rad Laboratories, Inc. will report financial results for the fourth quarter and full year 2021 on Thursday, February 10, 2022, following the close of the market.

INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), today announced that the company has entered into a pre-clinical research collaboration with Chinese University of Hong Kong (CUHK) to evaluate INKmune™ -- the company’s pseudokine NK cell priming platform -- in nasopharyngeal cancer (NPC), a type of head and neck cancer.

Neurophth Therapeutics, Inc., (hereinafter referred to as “Neurophth”), today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the Company’s leading gene therapy drug candidate, NR082 (rAAV2-ND4), for the treatment of Leber’s hereditary optic neuropathy (LHON) associated with mtND4 mutation.

HIL Applied Medical, a global leader in developing a new class of Proton Therapy systems, together with its partner Proton International (P.I.), announced today that the companies have been awarded a $900K grant from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their ongoing collaboration with Monte Rosa Therapeutics to develop a cellular systems pharmacology model for cereblon (CRBN)-based molecular glue degraders (MGDs) targeting GSPT1.

Alira Health (www.alirahealth.com), a global healthcare consulting and technology firm, announced that it has acquired Self Care Catalysts, Inc., a digital health company headquartered in Toronto, Canada

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced an update to the Proprietary Laboratory Analyses (PLA) code for its comprehensive genomic profiling test, PGDx elio™ tissue complete.

Calysta, Inc. World-leading alternative protein producer, Calysta, has signaled its future intentions with the appointment of Dr Lori Giver, as Chief Science and Sustainability Officer.

SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SNIPR001.

Excellos, Incorporated, a cell therapy Contract Development and Manufacturing Organization, announces its official corporate launch and closing of $15M in growth funding from Telegraph Hill Partners.